Key Highlights

  • DNA shares are trading up 11.33% to $11.16, against a prior close of $10.02.
  • A reported collaboration agreement with an Agenus subsidiary carried no disclosed terms.
  • Second-quarter revenue was $20.2 million, with a net loss of $46.7 million.
  • The company held about $302 million in cash.
  • Third-quarter earnings are estimated around November 5.

Reported Agenus Subsidiary Collaboration Draws Buyers

Ginkgo Bioworks (NYSE:DNA) shares are trading up 11.33% to $11.16 after a report that a subsidiary of Agenus (NASDAQ:AGEN) signed a collaboration agreement with the company. The report gave no deal terms, so the details and financial impact are unclear. Shares opened at $10.12, and the 52-week range runs from $5.37 to $18.22.

Sentiment toward AI-linked biotech tools names also improved after an AI developer's IPO filing outlined a push into life sciences and AI-driven lab automation, though no source links that filing directly to Ginkgo.

Autonomous Lab Infrastructure Replaces the Bespoke R&D Model

Ginkgo, based in Boston and founded in 2008, provides a cell engineering platform and is shifting from bespoke outsourced R&D toward autonomous lab infrastructure. Its offerings include Reconfigurable Automation Cells, Cloud Lab remote experimentation, Data Points datasets for AI and machine learning, AI models and biosecurity offerings under the Canopy and Horizon names.

Customers include pharmaceutical and biotech, agriculture, industrial, food, consumer and government and defense customers. Revenue comes from service fees, tool and hardware sales and potential downstream royalties or milestones.

Quarterly Revenue of $20.2 Million Against a $46.7 Million Loss

The company reported second-quarter revenue of $20.2 million and a net loss of $46.7 million, with about $302 million in cash. It carries a market cap of $751.18 million and a loss of $5.01 per share, and the shares are volatile, with a beta near 1.8.

Volume is running below average, and the stock is outpacing the healthcare sector, with the State Street Health Care Select Sector SPDR ETF little changed, down 0.09%.

November 5 Earnings Estimate and Cash Burn Frame the Next Test

Third-quarter earnings are estimated around November 5. Ginkgo's investment case depends on commercializing its automation platform before sizable annual cash burn depletes its liquidity, and the collaboration terms, once disclosed, will show how material the agreement is.